The FDA on July 9, 2021 approved PADCEV®, a Nectin-4-directed antibody and microtubule inhibitor conjugate, for adult patients with locally advanced or metastatic urothelial cancer who
- have previously received a Programmed Death receptor-1 (PD-1) or Programmed Death-Ligand (PD-L1) inhibitor and Platinum-containing chemotherapy, or
- are ineligible for Cisplatin-containing chemotherapy and have previously received one or more prior lines of therapy.
PADCEV® is a product of Astellas Pharma US, Inc.
